Ciclopirox nail lacquer topical solution 8%.
Ciclopirox nail lacquer 8% (Penlac, Aventis Pharma) was approved by the US FDA in December 1999, as a component of a comprehensive management program, for use in immunocompetent patients who have mild to moderate onychomycosis of the fingers and toes without lunula involvement due to Trichophyton rubrum. The comprehensive management program includes removal of the unattached, infected nails as frequently as once per month, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. The nail lacquer is not approved in Canada.
Gupta
A K
AK
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077768:Ciclopirox; D002986:Clinical Trials as Topic; D006801:Humans; D014009:Onychomycosis / Q000188:drug therapy*; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use*; D014249:Trichophyton
D000935:Antifungal Agents; D011728:Pyridones; D000077768:Ciclopirox